Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline-Reference-Cited by-同舟云学术

Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline

Published:2018-03 Issue:3 Volume:16 Page:378-384.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Gawron Andrew J.,Bielefeldt Klaus

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference38 articles.

1. Drugs@FDA: FDA Approved Drug Products; 2015. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206940). Accessed April 17, 2017.

2. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study;Dove;Gastroenterology,2013

3. Eluxadoline for irritable bowel syndrome with diarrhea;Lembo;N Engl J Med,2016

4. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea;Cash;Am J Gastroenterol,2017

5. Acute pancreatitis;Talukdar;Curr Opin Gastroenterol,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review;Archiv der Pharmazie;2024-07-23

2. Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database;Clinical Pharmacology & Therapeutics;2024-01-02

3. Adverse Drug Reaction Analysis Methods and Research Trends by Data Sources for Post-marketing Surveillance;Journal of Health Informatics and Statistics;2022-11-30

4. Pancreas and Adverse Drug Reactions: A Literature Review;Drug Safety;2022-07-05

5. A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder;BioMed Research International;2021-11-23